CMO SUPPLIER QUALITY AGREEMENTS - HOW TO COMPLY WITH NEW FDA AND EU GUIDELINES FOR CONTRACT DRUG MANUFACTURE

Website OnlineAudioTraining | Edit Freely

Category

Deadline: January 25, 2017 | Date: January 25, 2017

Venue/Country: 5042 Wilshire Blvd, Los Angeles, CA 90036, USA, U.S.A

Updated: 2017-01-12 16:32:14 (GMT+9)

Call For Papers - CFP

In 2010, the global CMO market was estimated at $26 billion dollars. Year on year growth has been 10.7% since 2008. The increasing use of outsourcing in the pharmaceutical industry along with recent well publicized quality issues with CMOs, make it a necessity to have excellent quality oversight of external manufacturers to provide assurance of GMP compliance. A Quality Agreement is one tool used to accomplish this objective.

This Webinar presentation will provide a thorough understanding of the content that is expected in Quality Agreements from a regulatory perspective.

Why Should Attend?

Manufacturing Organizations has always been a requirement of the FDA and EU. With the issuance of these new regulatory documents; the expectation is that there will be a written documentation of this control. Proof of this control can be presented to FDA / EU inspectors in the form of a Quality Agreement which is specific to a particular CMO.

Each proposed section of a Quality Agreement is fully analyzed and suggested content is written with the new guidelines taken into consideration. Comparison of the two regulatory documents is presented with differences highlighted and discussed.

Detailed discussion of Quality Agreement topics such as change control, documentation, facilities and equipment, lab controls, sub-contracting, etc. is covered.

The latest status of the FDA draft guidance is discussed and a review of comments from industry is included.